Drug Information

General Information
Drug ID
DR00283
Drug Name
Dopamine
Synonyms
(3H)-Dopamine; 1,2-Benzenediol, 4-(2-aminoethyl)-(9CI); 1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride; 1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium; 153C5321-5FEE-4B0B-8925-F388F0EEEBD1; 2-(3,4-dihydroxyphenyl)ethylamine; 2-benzenediol; 3,4-Dihydroxyphenethylamine hydrochloride; 3,4-Dihydroxyphenylethylamine; 3,4-dihydroxyphenethylamine; 3-Hydroxtyramine; 3-Hydroxytyramine; 3-Hydroxytyramine Hydrobromide; 3-Hydroxytyramine hydrochloride; 4-(2-Aminoethyl)-1; 4-(2-Aminoethyl)-1,2-benzenediol; 4-(2-Aminoethyl)-1,2-bezenediol; 4-(2-Aminoethyl)benzene-1,2-diol; 4-(2-Aminoethyl)catechol; 4-(2-Aminoethyl)pyrocatechol; 4-(2-Aminoethyl)pyrocatechol hydrochloride; 4-(2-aminoethyl)-pyrocatechol; A-(3,4-Dihydroxyphenyl)-b-aminoethane; ASL 279; Alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane; Beta-(3,4-Dihydroxyphenyl)ethylamine hydrochloride; Dopamin; Dopamina; Dopamina [INN-Spanish]; Dopamine (INN); Dopamine (USAN)(*hydrochloride*); Dopamine [INN:BAN]; Dopaminum; Dopaminum [INN-Latin]; Dophamine; Hydroxytyramin; Hydroxytyramine; IP 498; Intropin; Intropin [*hydrochloride*]; KW-3-060; L-DOPAMINE; LDP; M-Hydroxytyramine hydrochloride; Medopa (TN); Oxytyramine; Pyrocatechol, 4-(2-aminoethyl)-(8CI); Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride; Revimine
Drug Type
Small molecular drug
Indication Parkinson's Disease [ICD11: 8A00.0] Approved [1]
Therapeutic Class
Cardiotonic Agents
Structure
3D MOL 2D MOL
Formula
C8H11NO2
Canonical SMILES
C1=CC(=C(C=C1CCN)O)O
InChI
InChI=1S/C8H11NO2/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,10-11H,3-4,9H2
InChIKey
VYFYYTLLBUKUHU-UHFFFAOYSA-N
CAS Number
CAS 51-61-6
Pharmaceutical Properties Molecular Weight 153.18 Topological Polar Surface Area 66.5
Heavy Atom Count 11 Rotatable Bond Count 2
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 3
XLogP
-1
PubChem CID
681
PubChem SID
11111282 , 11335955 , 11361194 , 11363906 , 11364800 , 11364894 , 11366468 , 11367362 , 11367456 , 11369030 , 11369924 , 11370018 , 11371252 , 11372964 , 11373057 , 11374268 , 11375524 , 11375618 , 11377192 , 11378091 , 11378187 , 11462166 , 11484941 , 11488839 , 11490222 , 11492340 , 11494826 , 11534314 , 15170929 , 24439043 , 26612791 , 26719173 , 26750067 , 26753786 , 26753787 , 3133522 , 37024415 , 4396596 , 444583 , 46506043 , 47213204 , 6517 , 7888623 , 794678 , 7979122 , 8026221 , 8145174 , 8150742 , 840958 , 841083
ChEBI ID
ChEBI:18243
TTD Drug ID
D0T7OW
DT(s) Transporting This Drug DAT1 Transporter Info Sodium-dependent dopamine transporter Substrate [2]
OCT-1 Transporter Info Organic cation transporter 1 Substrate [3]
OCT-2 Transporter Info Organic cation transporter 2 Substrate [4]
SV2C Transporter Info Synaptic vesicle glycoprotein 2C Substrate [5]
VMAT1 Transporter Info Vesicular amine transporter 1 Substrate [6]
VMAT2 Transporter Info Vesicular amine transporter 2 Substrate [6]
Drug-Transporter Activity Data
Drug-Transporter Activity Data OCT-2 Transporter Info Km = 330 microM Human embryonic kidney cells (HEK293)-OCT2 [7]
OCT-2 Transporter Info Km = 1400 microM Human embryonic kidney cells (HEK293)-OCT2 [4]
OCT-2 Transporter Info Km = 390 microM Oocytes-OCT2 [7]
References
1 Dopamine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Characterization of VNTRs Within the Entire Region of SLC6A3 and Its Association with Hypertension. DNA Cell Biol. 2017 Mar;36(3):227-236.
3 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
4 Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
5 Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease. Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):E2253-E2262.
6 SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2-3):360-72.
7 Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol. 1998 Aug;54(2):342-52.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.